Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Releases New Regs To Step Up Quality Control For Essential Drugs; Second Part Of EDL Expected In November

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - In the latest effort to strengthen drug safety measures in China, China's State FDA issued Sept. 24 a new quality control regulation for drugs listed on the Essential Drug List. The regulation asks local FDAs to conduct at least two inspections every year of all manufacturing sites for drugs listed

You may also be interested in...



Facing Pricing Pressure And Generic Erosion, Simcere Shifts To Innovative Products For Future Growth: China Earnings Roundup (Part I)

China’s healthcare industry saw slower growth in the third quarter. In a recurring feature, PharmAsia News combs through earnings reports to bring you highlights of China’s leading pharma companies and how their efforts affect different sectors of the industry.

China State FDA Reforms Expected, But When?

China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question on manufacturers' minds is, how soon

China State FDA Reforms Expected, But When?

China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question on manufacturers' minds is, how soon

Related Content

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel